The Roswell Park Cancer Institute has had a long tradition of contributing to the national cooperative groups over many decades. Those contributions have been scientific, administrative, and participatory (over 1200 patients have been enrolled in cooperative group trials over the last 5 years). Contributions have been consistent and numerous over the years. This application summarizes the intent of its 4 Co-PIs (Dr. Levine/Dr. Adjei/Dr. Lele/Dr. Singh) and the membership of RPCI to sustain its commitment to the many strengths inherent to cooperative group research: therapeutic advances;a better understanding of the biology of cancer;cancer prevention;means to improve the quality of life of cancer patients;piloting of new drugs and radiology and radiation and surgical techniques;establishing the relevance of new cellular and molecular advances to the predictive, prognostic, and therapeutic approaches to patients;and the advancement of patient advocacy. Investigators at RPCI and its supporting staff fully recognize the essential importance of the timely and accurate submission of data and specimens to achieve these aims.
The aim of inter-Institutional cooperative clinical research is to advance our understanding of malignant diseases and, thereby, improve our ability to treat people afflicted with them. These aims are accomplished by resolving scientific questions of importance regarding cancer biology and therapy through the cooperation of selected Institutions that can pool their intellectual, technical, and patient resources. The rapid accumulation of clinical data and experience through cooperative research expedites progress in cancer therapy.
|Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506|
|Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180|
|Roboz, Gail J; Mandrekar, Sumithra J; Desai, Pinkal et al. (2018) Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv 2:3608-3617|
|Mullen, Elizabeth A; Chi, Yueh-Yun; Hibbitts, Emily et al. (2018) Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol :JCO1800076|
|Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539|
|Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348|
|Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545|
|Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58|
|Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442|
|Wang, Xiaofei; Wang, Xiaoyi; Hodgson, Lydia et al. (2017) Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist 22:189-198|
Showing the most recent 10 out of 19 publications